Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Metastatic × fludarabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 214 Precursor Cell Lymphoblastic Leukemia-Lymphoma 129 Myelodysplastic Syndromes 126 Leukemia, Lymphocytic, Chronic, B-Cell 126 Leukemia 114 Multiple Myeloma 107 Lymphoma 106 Lymphoma, Non-Hodgkin 104 Hematologic Neoplasms 69 Recurrence 66 Melanoma 64 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 64 Hodgkin Disease 64 Lymphoma, B-Cell 56 Lymphoma, Mantle-Cell 48 Lymphoma, Follicular 48 Lymphoma, Large B-Cell, Diffuse 46 Myeloproliferative Disorders 39 Burkitt Lymphoma 38 Ovarian Neoplasms 36 Neoplasms 35 Neoplasm Metastasis 28 Lymphoma, B-Cell, Marginal Zone 28 Graft vs Host Disease 26 Leukemia, Biphenotypic, Acute 25 Breast Neoplasms 25 Carcinoma, Non-Small-Cell Lung 24 Primary Myelofibrosis 23 Neoplasms, Plasma Cell 23 Pancreatic Neoplasms 20

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡